The partnership between Clinerion and OncologyInformationService (O.I.s) will create a platform for oncology which integrates O.I.s’s real-world databases with Clinerion’s patient data network, via Clinerion’s patented patient data analytics technologies. The partners aim to establish a real-world evidence (RWE) database from a network of cancer treating institutions which will also allow real-time query of the participating institutions’ electronic medical records (EMRs). This platform will leverage the aggregated data to deliver:
O.I.s provides a deep knowledge of treatment algorithms in oncology and hematology and approved methodologies for collection and analyses of treatment algorithms based on longitudinal real-world data from patient files in treating institutions. O.I.s will provide the Clinerion partnership with access to its established RWE cooperative group consisting of patient organizations and a network of oncologists/hematologists, its real-world databases and its approved methodologies for collecting and analyzing RWE data.
Clinerion’s Patient Network Explorer (PNEx) allows query of anonymized patient data among its network of partner hospitals to generate real-world data based on EMR. In the partnership, Clinerion will provide PNEx technology as the platform to query both partners’ databases, taking advantage of its fast data collection and real-time update capability.
The partners’ new platform will also incorporate genomic technology and PRO/PRE reporting via an additional partnership with Andaman7.
“The partnership with Clinerion will allow O.I.s to provide unbiased and complete RWE faster than before and to involve cancer-treating institutions, globally. O.I.s will use the resulting enormous, combined database for high-end analyses, meeting the information needs from all stakeholders in the fight against cancer,” saysLenka Kellermann, founder and owner of O.I.s.
“This partnership represents a deepening of Clinerion’s commitment to providing our real-world data solutions in the oncology space, which represents 40% of all drug development pipeline expenditure,” says Ian Rentsch, CEO of Clinerion. “Clinerion’s services are otherwise agnostic to treatment area, being based on hospital EMR data.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.